{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.","groups":[{"description":"Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 35 cycles (up to approximately 2 years).","id":"OG000","title":"Cohort A - Pembrolizumab 200 mg"},{"description":"Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants received pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 35 cycles (up to approximately 2 years).","id":"OG001","title":"Cohort B - Pembrolizumab 200 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Number of Participants Who Experienced an Adverse Event (AE).","type":"SECONDARY","unitOfMeasure":"Participants"}